- Previous Close
38.10 - Open
38.20 - Bid --
- Ask --
- Day's Range
37.30 - 38.40 - 52 Week Range
35.45 - 49.30 - Volume
7,385 - Avg. Volume
0 - Market Cap (intraday)
2.19B - Beta (5Y Monthly) 0.87
- PE Ratio (TTM)
16.42 - EPS (TTM)
2.29 - Earnings Date Apr 25, 2025
- Forward Dividend & Yield 2.00 (5.56%)
- Ex-Dividend Date Mar 21, 2025
- 1y Target Est
--
BB Biotech AG is an equity fund launched and managed by Bellevue Asset Management AG. The fund invests in the public equity markets across the globe. It primarily invests in stocks of companies that are engaged in medications and diagnostics based on modern biotechnology. The fund employs a fundamental analysis to create its portfolio. BB Biotech AG was formed on November 09, 1993 and is domiciled in Switzerland.
www.bbbiotech.ch/en/bb-biotech/Recent News: BIONZ.XC
View MorePerformance Overview: BIONZ.XC
Trailing total returns as of 2/24/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BIONZ.XC
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BIONZ.XC
View MoreValuation Measures
Market Cap
2.05B
Enterprise Value
--
Trailing P/E
15.70
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
14.92
Price/Book (mrq)
0.88
Enterprise Value/Revenue
17.93
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
67.99%
Return on Assets (ttm)
1.99%
Return on Equity (ttm)
3.29%
Revenue (ttm)
111.63M
Net Income Avi to Common (ttm)
75.9M
Diluted EPS (ttm)
2.29
Balance Sheet and Cash Flow
Total Cash (mrq)
2.41B
Total Debt/Equity (mrq)
5.14%
Levered Free Cash Flow (ttm)
43.55M